References
- Perumal JS, Foo F, Cook P, Khan O. Subcutaneous administration of alemtuzumab in patients with highly active multiple sclerosis. Mult. Scler. doi:10.1177/1352458511435716 (2012) (Epub ahead of print).
- Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 33(11), 1444–1452 (1983).
- Compston AC. McAlpine’s Multiple Sclerosis. Churchill Livingstone Elsevier, PA, USA (2006).
- Kappos L, Radue EW, O’Connor P et al. FREEDOMS Study Group. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N. Engl. J. Med. 362(5), 387–401 (2010).
- Polman CH, O’Connor PW, Havrdova E et al. AFFIRM Investigators. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N. Engl. J. Med. 354(9), 899–910 (2006).
- Horga A, Castillo J, Rio J et al. An observational study of the effectiveness and safety of natalizumab in the treatment of multiple sclerosis. Rev. Neurol. 52(6), 321–330 (2011).
- Köhler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 256(5517), 495–497 (1975).
- Klotz L, Meuth SG, Wiendl H. Immune mechanisms of new therapeutic strategies in multiple sclerosis-A focus on alemtuzumab. Clin. Immunol. 142(1), 25–30 (2012).
- Coles AJ, Compston DA, Selmaj KW et al. CAMMS223 Trial Investigators. Alemtuzumab vs. interferon beta-1a in early multiple sclerosis. N. Engl. J. Med. 359(17), 1786–1801 (2008).
- Coles AJ, Wing MG, Molyneux P et al. Monoclonal antibody treatment exposes three mechanisms underlying the clinical course of multiple sclerosis. Ann. Neurol. 46(3), 296–304 (1999).
- Hirst CL, Pace A, Pickersgill TP et al. Campath 1-H treatment in patients with aggressive relapsing remitting multiple sclerosis. J. Neurol. 255(2), 231–238 (2008).
- Dearden CE, Khot A, Else M et al. Alemtuzumab therapy in T-cell prolymphocytic leukemia: comparing efficacy in a series treated intravenously and a study piloting the subcutaneous route. Blood 118(22), 5799–5802 (2011).
- Bezares RF, Stemelin G, Diaz A et al. Multicenter study of subcutaneous alemtuzumab administered at reduced dose in patients with fludarabine-relapsed/refractory chronic lymphocytic leukemia: final analysis. Leuk. Lymphoma 52(10), 1936–1941 (2011).
- Martin R. Anti-CD25 (daclizumab) monoclonal antibody therapy in relapsing-remitting multiple sclerosis. Clin. Immunol. 142(1), 9–14 (2012).
- Wynn D, Kaufman M, Montalban X et al. CHOICE investigators. Daclizumab in active relapsing multiple sclerosis (CHOICE study): a Phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon beta. Lancet Neurol. 9(4), 381–390 (2010).
- Barun B, Bar-Or A. Treatment of multiple sclerosis with anti-CD20 antibodies. Clin. Immunol. 142(1), 31–37 (2012).
- Soelberg Sorensen P, Drulovic J, Havrdova E, Lisby S, Graff O, Shackelford S. Magnetic resonance imaging (MRI) efficacy of ofatumumab in relapsing-remitting multiple sclerosis (RRMS)- 24-week results of a Phase II study. Presented at: ECTRIMS. Gothenburg, Sweden, 13–16 October 2010.
- Jones JL, Phuah CL, Cox AL et al. IL-21 drives secondary autoimmunity in patients with multiple sclerosis, following therapeutic lymphocyte depletion with alemtuzumab (Campath-1H). J. Clin. Invest. 119(7), 2052–2061 (2009).
Websites
- Corp BIaAB. Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis (DECIDE); NCT01064401. http://clinicaltrials.gov
- GlaxoSmithKline. Ofatumumab Subcutaneous Administration in Subjects With Relapsing-Remitting Multiple Sclerosis (MIRROR); NCT01457924. http://clinicaltrials.gov/ct2/show/NCT01457924?term=GlaxoSmithKline.+Ofatumumab+Subcutaneous+Administration+in+Subjects+With+Relapsing-Remitting+Multiple+Sclerosis+%28MIRROR%29&rank=1